Initiated by Hubei Province, the largest Chinese patent medicine alliance in the history of 19 provinces in the field of health in China ended.
On December 24, the 21st Century Business Herald reporter learned from the Publicity Department of Hubei provincial Party committee that the 19 provincial Chinese patent medicine alliance focused on volume procurement, and 182 products from 157 enterprises participated in the quotation, with a procurement scale of nearly 10 billion yuan. 97 enterprises and 111 products were selected, with a selection rate of 62%. The average price of the proposed successful selection decreased by 42.27% and the maximum decreased by 82.63%.
Since 2019, China has carried out six batches of centralized drug procurement organized by the state, but it does not involve the field of Chinese patent medicine. This is because the academic and cultural characteristics of “one source and multiple streams” of traditional Chinese medicine are its uniqueness and difficulty. Due to its large number of “exclusive” products and high concentration, it is impossible to use consistency evaluation as the quality evaluation system. Therefore, before that, the centralized volume procurement of Chinese patent medicine alliance has not been carried out in China.
On January 22, 2021, the general office of the State Council issued the opinions on promoting the normalization and institutionalization of centralized drug procurement, which made it clear that “explore the combination of centralized drug procurement for different generic drugs with similar indications or functions”, which provided policy support for the centralized procurement of Chinese patent medicines.
According to the work arrangement of the national medical insurance administration, Hubei led 19 provinces to form an inter provincial alliance to carry out the centralized procurement of Chinese patent medicines, opened up a new field of centralized drug procurement and created a new path of centralized procurement of Chinese patent medicines.
It is understood that the dosage forms and specifications of the products selected in this centralized purchase are complete, and some recommended drugs of the eighth edition of covid-19 pneumonia diagnosis and treatment plan are covered. At present, most of the mainstream products used clinically and the recommended drugs of covid-19 pneumonia diagnosis and treatment plan are selected, which can effectively meet the drug needs of clinical and normalized epidemic prevention and control. According to the calculation of the annual demand of the 19 provincial alliance, it is estimated that the annual drug cost can be saved by more than 2.6 billion yuan.
According to the plan, the procurement results of the inter provincial alliance have been publicized. After the procurement results are officially announced, the 19 alliance provinces will organize the implementation of the agreed procurement volume, sign purchase and sales contracts, and implement the procurement results.
Gao Xin, deputy director of Hubei Medical Insurance Bureau, said: “the impact of the centralized purchase of Chinese patent medicines must be sustained and far-reaching. First, we explored the centralized purchase mode of Chinese patent medicines, opened a key first step, and provided replicable experience for the national centralized purchase of Chinese patent medicines. Second, Chinese patent medicines have many categories and wide uses, belonging to Lbx Pharmacy Chain Joint Stock Company(603883) Commonly used drugs cover a wide range of people, have a high utilization rate and a long course of treatment. By exchanging volume for price, it will greatly reduce the burden on patients and benefit a large number of ordinary people. Third, while reducing the burden on patients, the centralized purchase of Chinese patent medicine also fully considers the reasonable profits of the enterprise, and reduces the marketing cost of the enterprise through centralized purchase, It helps to squeeze out the unreasonable “water” in drug circulation and purify the market environment. Fourth, with the deepening of centralized procurement, it helps to promote the industry to improve the concentration in competition and promote product innovation and upgrading; fifth, it ensures Lbx Pharmacy Chain Joint Stock Company(603883) on the one hand through the establishment of scientific evaluation system and quality assurance measures On the other hand, it forces enterprises to pay more attention to production quality. In the long run, it has made up for the shortcomings of the quality evaluation system of the whole traditional Chinese medicine industry, and has an extremely far-reaching impact on the standardized development and high-quality development of the traditional Chinese medicine industry. ”
(21st Century Business Herald)
